A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasms.
A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasms.
复制标题
用于骨髓增生性肿瘤患者快速分子诊断检测的便携式微流体平台
DOI：
10.1038/s41598-017-08674-8
复制
发表时间：
2017-08-17
影响因子：
4.6
通讯作者：
Guan M
中科院分区：
文献类型：
--
作者：
Wang H;Zhang X;Xu X;Zhang Q;Wang H;Li D;Kang Z;Wu Z;Tang Y;An Z;Guan M
The ability to simultaneously detect JAK2 V617F and MPL W515K/L mutations would substantially improve the early diagnosis of myeloproliferative neoplasms (MPNs) and decrease the risk of arterial thrombosis. The goal of this study is to achieve a point of care testing platform for simultaneous analysis of major genetic alterations in MPN. Here, we report a microfluidic platform including a glass capillary containing polypropylene matrix that extracts genomic DNA from a drop of whole blood, a microchip for simultaneous multi-gene mutation screening, and a handheld battery-powered heating device. The µmLchip system was successfully used for point-of-care identification of the JAK2 V617F and MPL W515K/L mutations. The µmLchip assays were then validated by mutation analysis with samples from 100 MPN patients who had previously been analyzed via unlabeled probe melting curve analysis or real-time PCR. The results from the µmLchip were in perfect agreement with those from the other methods, except for one discrepant result that was negative in the unlabeled probe melting curve analysis but positive in the µmLchip. After T-A cloning, sequences of cloned PCR products revealed JAK2 V617F mutation in the sample. The portable microfluidic platform may be very attractive in developing point-of-care diagnostics for MPL W515K/L and JAK2 V617F mutations.
